Table 1 Characteristics of included studies
Study | Country | Design | Total number of people (n) | Initial cardiac rhythm (n) | Outcome indicators | Study | Country | Design | Total number of people (n) | Initial cardiac rhythm (n) | Outcome indicators | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Adrenaline group | Non-adrenaline group | Shockable | Non- Shockable | Adrenaline group | Non-adrenaline group | Shockable | Non- shockable | ||||||||
Jacobs 2011 | Australia | RCT | 272 | 262 | 245 | 289 | ROSC; survival to discharge; CPC at hospital discharge (CPC<3) | Baert 2020 | France | Cohort study | 24294 | 2714 | 3448 | 23560 | Survival at D30; ROSC; the neurological outcome at D30 |
Machida 2012 | Japan | Cohort study | 49 | 443 | 75 | 416 | ROSC: survival to hospital discharge; good neurologic recovery at hospital discharge | Dumas 2014 | France | Cohort study | 1134 | 422 | 845 | N/A | Favorable neurological outcome at discharge (CPC<3) |
Perkins 2018 | England | RCT | 4015 | 3999 | 1445 | 6221 | ROSC; survival at hospital discharge and at 3 months, and the neurologic outcomes at hospital discharge and at 3 months (MRS≤3) | Fukuda 2015 | Japan | Cohort study | 770 | 6301 | 845 | N/A | Favorable neurological status at 1 month; 1-month survival; ROSC |
Kaji 2014 | America | Cohort study | 160 | 24 | 66 | N/A | ROSC; survival to hospital discharge; survival with GCS of 14 or 15 | Fukuda 2016 | Japan | Cohort study | 33400 | 33400 | 8040 | 58760 | ROSC; 1-month survival; neurological status one month |
Hayakawa 2013 | Japan | Cohort study | 318 | 315 | 173 | 460 | ROSC; favorable neurological outcome 30 days; survival of 30 days | Nordseth 2012 | Sweden | RCT | 101 | 73 | N/A | 174 | ROSC; survival to discharge |
Goto 2013 | Japan | Cohort study | 23676 | 185901 | 15494 | 194085 | ROSC; survival at 1 month; survival at 1 month with favorable neurological outcome (defined as a CPC score of 1 or 2) | Hagihara 2012 | Japan | Cohort study | 15030 | 73 | 31157 | 386024 | ROSC; survival at 1 month; 1-month survival with CPC category 1 or 2 |
Neset 2013 | Sweden | Cohort study | 119 | 104 | 187 | 36 | Survival to hospital discharge | Yu Wang 2022 | China | Cohort study | 572 | 961 | N/A | N/A | ROSC; survival to hospital discharge |
Olasveengen 2012 | Sweden | Cohort study | 367 | 481 | 284 | 564 | ROSC; survival to hospital discharge; neurologic outcome at hospital discharge | Hayashi 2012 | Japan | Cohort study | 1013 | 2148 | 506 | 2655 | ROSC; 1-month survival; neurologically intact 1-month survival |
|  |  |  |  |  |  |  |  | Nakahara 2013 | Japan | Cohort study | 13421 | 82658 | 14943 | 81136 | Survival and neurologically intact survival with the Glasgow–Pittsburgh cerebral performance category score 1-2 at one month or at discharge |
| Â | Â | Â | Â | Â | Â | Â | Â | 2021 Matsuyama | Japan | Cohort study | 8467 | 14410 | N/A | N/A | 1-month survival; ROSC; 1-month survival with favorable neurological outcome |